Senti Biosciences SNTI 深 沪
已收盘 10-02 16:00:00 美东时间
0.3223
-0.002
-0.65%
华盛通- 最 高0.326
- 今 开0.3147
- 成交量 12.46万股
- 最 低 0.3104
- 昨 收 0.3244
- 总市值 1003.80万
- 52周最高 2.88
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 0.29
- 委 比 -80.59%
- 总股本 3114.48万
- 历史最高 87.70
- 量 比 0.25
- 振 幅 4.81%
- 历史最低 0.29
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senti Biosciences Files Prospectus Covering Resale Of Up To 25,555,024 Shares Of Common Stock Offered By The Selling Securityholders
SENTI BIOSCIENCES HOLDINGS, INC. 25,555,024 Shares of Common Stock Offered by the Selling Securityholders This prospectus relates to the offer and sale from time to time by the selling securityholders (the "Selling Securityholders") or their permitted transferees, of up to 25,555,024 shares (the "Re...
09-25 05:01
Senti Biosciences Secures Equity Commitment Amid Merger Plans
The latest update is out from Senti Biosciences ( ($SNTI) ). On September 3, 20...
09-04 18:28
Senti Biosciences to spin off its gene-circuit pipeline
Senti Biosciences Holdings (SNTI) on Wednesday said privately held NewCo controlled by affiliates of top investor Celadon will acquire its gene-circuit pipeline, including SENTI-202. Equity holders ar...
07-15 19:59
Senti Biosciences Signs Agreement To Sell Assets Related To Its Gene-Circuit-Enabled Pipeline To Celadon For Up To $60M In Milestone Payments Over Seven Years
Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) ("SBH" or the "Company") today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the "Retained Assets") and unlock value for its Gene-Ci...
07-15 19:33
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K
Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from
05-14 20:46
Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable
05-14 20:43
Senti Biosciences Enters Up To $40M Convertible Note Financing Agreement With Celadon Affiliate
Securities Purchase Agreement On April 27, 2026, Senti Biosciences Holdings, Inc. (the "Company"), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company ("Senti Holdings"), and Senti Biosciences,
05-02 04:11
